Physician profile
John Rocco Macmillan Rodney
NPI 1891944708
$251,298.72
in general payments reported to CMS, 2019-2025
8 companies · $137K in 2025
The $137K reported for 2025 was more than what 99% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2023: $12K · 2024: $103K · 2025: $137K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $207K · Travel and Lodging: $39K · Food and Beverage: $5,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $206,707.50 |
| Travel and Lodging | $38,859.60 |
| Food and Beverage | $5,619.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $251,038.57 | 2023-2025 | Brixadi |
| Abbvie INC. | $111.95 | 2021 | |
| Indivior INC. | $45.21 | 2023 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.60 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $21.51 | 2025 | |
| Merck Sharp & Dohme LLC | $21.30 | 2025 | Enflonsia |
| Otsuka America Pharmaceutical, INC. | $18.51 | 2025 | Rexulti |
| Alkermes, INC. | $14.07 | 2025 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rocco Rodney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.